Research programme: gap junction protein mediated hearing loss gene therapies - Akouos
Alternative Names: GJB2 gene therapies - Akouos; Hearing loss gene therapies - AkouosLatest Information Update: 28 Sep 2025
At a glance
- Originator Akouos
- Class Ear disorder therapies; Gene therapies
- Mechanism of Action Gene transference; GJB2 protein replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Hearing loss
Most Recent Events
- 28 Sep 2025 No recent reports of development identified for research development in Hearing loss in USA (Parenteral)
- 31 Oct 2024 Gap junction protein mediated hearing loss gene therapies is still in early research phase for Hearing loss in USA (Parenteral) (Akouos pipeline, October 2024)
- 01 Dec 2022 Akouos has been acquired by Eli Lilly and Company